|4.66||-0.3788||-7.52%||Vol 11.92K||1Y Perf 169.52%|
|Oct 4th, 2023 15:51 DELAYED|
|- -||- -%|
|Target Price||12.33||Analyst Rating||Strong Buy 1.00|
|Potential %||164.52||Finscreener Ranking||— -|
|Insiders Trans % 3/6/12 mo.||-/-/100||Value Ranking||★★★ 50.88|
|Insiders Value % 3/6/12 mo.||-/-/100||Growth Ranking||— -|
|Insiders Shares Cnt. % 3/6/12 mo.||-/-/100||Income Ranking||— -|
|Price Range Ratio 52W %||-0.52||Earnings Rating||—|
|Market Cap||7.48M||Earnings Date||9th Nov 2023|
Today's Price Range
|Moving Averages:||Strong Sell|
|6 Months||1 261.79%|
|Earnings History||Estimate||Reported||Surprise %|
|Earnings Per End||Estimate||Revision %||Trend|
|Next Report Date||9th Nov 2023|
|Estimated EPS Next Report||-5.67|
|EPS Growth Next 5 Years %||-|
|Avg. Weekly Volume||5.20K|
|Avg. Monthly Volume||6.64K|
|Avg. Quarterly Volume||10.06K|
Finch Therapeutics Group Inc. (NASDAQ: FNCH) stock closed at 5.04 per share at the end of the most recent trading day (a -5% change compared to the prior day closing price) with a volume of 6.29K shares and market capitalization of 7.48M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 131 people. Finch Therapeutics Group Inc. CEO is Mark Smith.
The one-year performance of Finch Therapeutics Group Inc. stock is 169.52%, while year-to-date (YTD) performance is 950%. FNCH stock has a five-year performance of %. Its 52-week range is between 4.95 and 60, which gives FNCH stock a 52-week price range ratio of -0.52%
Finch Therapeutics Group Inc. currently has a PE ratio of -0.20, a price-to-book (PB) ratio of 0.19, a price-to-sale (PS) ratio of 26.67, a price to cashflow ratio of -, a PEG ratio of -, a ROA of -50.69%, a ROC of -47.91% and a ROE of -62.64%. The company’s profit margin is -%, its EBITDA margin is -4 936.50%, and its revenue ttm is $853.00 Thousand , which makes it $0.02 revenue per share.
Of the last four earnings reports from Finch Therapeutics Group Inc., there were 1 positive earnings surprise and 3 negative earnings surprise. The company has EPS estimate of $-5.67 for the next earnings report. Finch Therapeutics Group Inc.’s next earnings report date is 09th Nov 2023.
The consensus rating of Wall Street analysts for Finch Therapeutics Group Inc. is Strong Buy (1), with a target price of $12.33, which is +164.52% compared to the current price. The earnings rating for Finch Therapeutics Group Inc. stock is (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Finch Therapeutics Group Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
Finch Therapeutics Group Inc. has a Sell technical analysis rating based on Technical Indicators (ADX : 15.82, ATR14 : 0.46, CCI20 : -157.00, Chaikin Money Flow : -0.25, MACD : -0.38, Money Flow Index : 42.69, ROC : -12.20, RSI : 30.54, STOCH (14,3) : 6.19, STOCH RSI : 0.00, UO : 52.06, Williams %R : -93.81), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Finch Therapeutics Group Inc. in the last 12-months were: Blaustein Marc (Sold 4 619 shares of value $1 755 ), Graf Susan (Buy at a value of $1 353), Joseph Vittiglio (Sold 3 636 shares of value $5 054 ), Marc Blaustein (Sold 8 255 shares of value $6 809 )
Copyright © 2016-2023 Finscreener.org. All Rights Reserved.
Disclaimer: Before deciding to trade you should carefully consider your investment objectives, level of experience and your risk appetite. Forex data is a real-time with a 30 second refresh. Prices may not be accurate and may differ from the actual market price. Prices on the website are indicative and solely for informational purposes, not for trading purposes or advice. Please be aware of the risks associated with trading the on financial markets, it is one of the riskiest investment forms. Past performance does not guarantee future profits. We take no responsibility for any losses that may arise as a result of the data contained on this website. The content and the website are provided "as is", without any warranties. In no event will Finscreener.org, its employees, owners, directors, affiliates, partners, data provider, third party or anyone else liable to anyone else for any decision made regarding information on this website.
General partner of Finscreener is SLOVAKODATA, a.s.
This could take some time, please wait.